EDITORIAL
Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity
Integrating spatial profiling, single-cell technologies and blood-based correlates may help reveal why immunotherapy is effective in some tumours but not others
IMMUNOTHERAPY
Novel strategies to overcome resistance to immune checkpoint inhibitors show promise in early studies
Blocking GDF-15, an mRNA-based therapy and targeting VISTA have a strong mechanistic rationale, resulting in clinical benefit in heavily pre-treated patients
First-in-human trial of a TCR-T therapy targeting KRAS G12V reports a significant response rate
Preliminary results of NW-301V are promising, with a lack of severe adverse effects at all doses tested in patients with pancreatic cancer or colorectal cancer
Sustained benefits of neoadjuvant immunotherapy demonstrated in resectable melanoma
Longer follow-up from two studies supports neoadjuvant over adjuvant immune checkpoint inhibition in patients with resectable melanoma and clinically or radiologically detectable metastasis, plus useful insights gained from biomarker analyses will help refine treatment strategies
FROM THE ESMO ASIA CONGRESS 2025
A new claudin 18.2-targeting approach appears promising in gastric cancers
A triple combination investigated in a phase I trial adds to the growing therapeutic options directed at this emerging target
First-in-class p53 reactivator shows activity in advanced solid tumours
Initial results of a phase II trial with rezatapopt suggest real promise in an area that has eluded druggable targeting
177Lu-DOTATATE prolongs progression-free survival in previously treated advanced GEP-NETs
Impressive results from the Chinese LUMINET-1 phase III study confirm and extend previous findings in Western patients
Access to targeted treatments for patients with CUP is still an issue
Studies underline that a tumour-agnostic approach may help improve treatment options
Novel ADCs from Asia open new clinical opportunities
Phase I–II studies showcase the clinical potential of novel ADCs with enhanced targeting and/or payload strategies
Population diversity in cancer treatment – differences matter
Recognising diversity is essential to providing effective, well tolerated and accessible cancer care globally
AI & DIGITAL ONCOLOGY
The first ESMO guidance for AI-based biomarkers
In a newly released framework paper, ESMO defines criteria for assessing and implementing AI-based biomarkers in oncology
Harnessing Large Language Models in oncology: ESMO’s framework for integration in the clinic
The ELCAP statements, developed by a group of international experts, help oncology stakeholders recognise the opportunities and the risks of these artificial intelligence systems by categorising them into three types
How AI is expediting clinical research: the use of synthetic real-world data
While synthetic real-world data may help overcome current challenges in clinical trials, it also introduces new complexities
OPINIONS
Artificial intelligence is expediting the development of therapeutic immunotherapies
Sine Reker Hadrup
Going beyond protocol is key for young people with cancer
Eileen Poon
AI-powered three-dimensional tumour pathology
Faisal Mahmood
Artificial intelligence as a reliable research partner
Shekoofeh Azizi
OPINIONS
Artificial intelligence is expediting the development of therapeutic immunotherapies
Sine Reker Hadrup
Going beyond protocol is key for young people with cancer
Eileen Poon
AI-powered three-dimensional tumour pathology
Faisal Mahmood
Artificial intelligence as a reliable research partner
Shekoofeh Azizi